Companies in #Immunology

AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. AbbVie develops and commercializes therapeutics across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Epkinly), neuroscience (Vraylar, Duopa), and aesthetics (Botox, Juvederm), with growing investments in oncology, neuroscience, and eye care.

Abcuro is a clinical-stage biopharmaceutical company developing first-in-class immunotherapies targeting immunomodulatory receptors for autoimmune diseases and cancer, including a late-stage program for inclusion body myositis.

Akesobio is a Chinese clinical-stage biopharmaceutical company developing innovative antibodies for oncology and inflammatory diseases, including the PD-1xVEGF bispecific ivonescimab partnered with Summit Therapeutics.

Antares Therapeutics is a clinical-stage small molecule biopharmaceutical company developing oral and injectable therapies for autoimmune and inflammatory diseases. The company is headquartered in Princeton, New Jersey, and was acquired by Novartis in 2026.

BioNTech is a public biotechnology company developing mRNA-based medicines, cancer immunotherapies, infectious-disease vaccines, and antibody-based oncology programs.

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.

Global biopharmaceutical company (NYSE: BMY) focused on oncology, hematology, immunology, cardiovascular, neuroscience and fibrotic disease; marketed assets include Opdivo (nivolumab), Yervoy, Revlimid, Eliquis (apixaban with Pfizer), Pomalyst, Sprycel, Reblozyl, Sotyktu, deucravacitinib and the cardio-failure drug Camzyos; major acquisitions: Celgene ($74B, 2019), MyoKardia ($13B, 2020), Turning Point Therapeutics ($4.1B, 2022), Karuna Therapeutics ($14B, 2024), RayzeBio ($4.1B, 2024).

Global mid-sized Contract Research Organization (CRO) operating in 23 countries, providing patient-centric clinical trial solutions for biopharma innovators across oncology, rare disease, and cell & gene therapy programs.

Caldera Therapeutics is a privately held biopharmaceutical company developing targeted therapies for immunology and inflammation. In 2026, the company announced plans to go public via a reverse merger transaction raising approximately $478M collectively with Vidya Therapeutics.

Global healthcare media and marketing agency specializing in pharmaceutical and life sciences brand strategy, media planning, and medical communications. A WPP company.

Crystalys Therapeutics is a clinical-stage biotechnology company developing dotinurad, a Phase 3-ready URAT1 inhibitor for the treatment of gout. The company's lead asset is positioned to rival Sobi's gout franchise.

Clinical-stage biopharmaceutical company developing Immuno-STAT biologics designed to selectively engage disease-relevant T cells for cancer and autoimmune disease; its CUE-221 candidate for chronic spontaneous urticaria hit its Phase 2 primary endpoint in September 2026.

South San Francisco biotech pioneering next-generation bispecific antibodies for immunology and inflammation using its DualScreen bispecific discovery engine.

Eli Lilly and Company is a major global pharmaceutical company with a broad portfolio spanning diabetes/obesity, oncology, neuroscience, immunology, and rare diseases. Its GLP-1 franchise (Mounjaro/tirzepatide, Zepbound) and the oral GLP-1 candidate orforglipron are reshaping obesity care. Lilly has been the most aggressive large-pharma dealmaker of the past decade, completing more biotech buyouts than any other top-12 pharma by revenue, with 10 acquisitions in 2026 alone accounting for roughly half of pharma's total M&A capacity (~$25B+ committed).

Formation Bio is an AI-native drug development company building a clinical-stage pipeline through in-licensing and asset acquisition, with a focus on using technology and AI to accelerate clinical trial execution. In early 2026, the company launched a new subsidiary, Kenmare Bio, to develop a miR-124 inhibitor licensed from a Chinese partner for inflammatory diseases.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Generate Biomedicines, Inc. (NASDAQ: GENB) is a clinical-stage generative-biology company headquartered in Somerville, Massachusetts, using machine learning and its Generate Platform to program novel protein therapeutics; it went public in February 2026 and is a Flagship Pioneering-founded company whose lead programs span immunology (GB-0895 anti-TSLP) and oncology (GB-4362, GB-5267).

Services: Pharmaceutical medicines, vaccines, consumer healthcare; specialty medicines in HIV, oncology, respiratory; vaccines for hepatitis, HPV, meningitis.

R&D-driven pharmaceutical company focused on new drug development, synthesis, and manufacturing based in Chengdu, China.

HUTCHMED is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. The company has licensed its dual-action KRAS/EGFR cancer drug to GSK for $110 million upfront.

AI-driven small molecule drug discovery company whose Enchant platform combines generative models such as NeuralPLexer with high-throughput experimentation to design therapeutics; partnered with AbbVie and Revolution Medicines.

Protein-engineering and single-domain antibody platform company developing therapeutic candidates for oncology and rare diseases. Nasdaq: INBX.

Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.

Insilico Medicine is an end-to-end generative artificial intelligence-driven drug discovery company connecting biology, chemistry, and clinical trials analysis.

Clinical-stage biotechnology company developing monoclonal antibodies for infectious diseases, with a focus on long-acting immunologic prophylaxis. Lead product pemivibart targets SARS-CoV-2 prevention.

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation operating through two business segments: Innovative Medicine and MedTech. It is one of the world's largest and most diversified healthcare companies, with products spanning oncology, immunology, neuroscience, cardiovascular, and surgical technologies.

Global biopharmaceutical company specializing in plasma-derived products for rare and serious diseases.

Kyowa Kirin Co., Ltd. is a Japanese specialty pharmaceutical and biotechnology company under the Kirin Holdings group, focused on developing innovative antibody-based drugs for cancer, kidney disease, immune system diseases, and rare diseases. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Kyowa Kirin is the Japan-based parent of Kyowa Kirin, Inc. (the US subsidiary), and operates as a research-driven biopharma with multiple approved biologics including poteligeo (mogamulizumab, for cutaneous T-cell lymphoma) and Crysvita (burosumab, for X-linked hypophosphatemia). The company announced a $530M biologics manufacturing facility in Sanford, North Carolina in June 2024 — its first US manufacturing site — which was selected in June 2026 for the FDA PreCheck Pilot Program. Kyowa Kirin's US subsidiary (KKNA) operates the Sanford facility and supports the company's clinical and commercial biologics pipeline including rocatinlimab for atopic dermatitis.

Clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery, which leverages evolutionary insights from fungi to develop next-generation precision medicines. In August 2026 it raised a combined $263 million (Series D + Series F) to support the clinical program for LIFE-001, under development to prevent organ failure.

Biotech developing precision immunology and inflammation medicines, with a pipeline piece licensed from Kira Pharmaceuticals targeting the Tavneos (C5aR) space.

Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company with a portfolio spanning immunology, central nervous system disorders, diabetes, and vaccines. It is the originator of Radicava (edaravone) for ALS and has been divesting non-core plants as part of a post-buyout strategic pivot.

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.

Swiss-headquartered plasma products company specializing in coagulation factor therapies (wilate, Nuwiq) for hemophilia and von Willebrand disease, with operations across 40+ countries.

Danish biotech whose nGen platform discovers fully synthetic oral macrocyclic peptides (nCycles) that pair biologic-like target specificity with the convenience of an oral pill.

Orionis Biosciences is a life sciences company pioneering conditionally active immunotherapies (A-Kines) and molecular glue drug discovery (AlloGlues) for cancer and immunology. The company has research collaborations with Novartis and Genentech/Roche, and is advancing internal programs in oncology and immunology.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. The company develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.

RayThera is a San Diego-based private biotech developing small-molecule therapeutics in immunology. Founded in 2023 with a $110M Series A, the company is being acquired by Biogen in a deal worth up to $1B, marking a major exit for the immunology-focused startup.

Clinical-stage biopharmaceutical company that builds and launches modular subsidiary companies (Vants) developing transformative therapies across immunology, neurology, oncology, and rare disease.

Sandoz is a global leader in generic pharmaceuticals and biosimilars, spun off from Novartis in 2023 to focus on off-patent medicines across immunology, oncology, infectious diseases, and metabolic disorders.

Sanofi (NASDAQ: SNY; Euronext: SAN) is a global biopharmaceutical company with major franchises in immunology (Dupixent, partnered with Regeneron), vaccines (Beyfortus, Fluzone, Dengvaxia), rare disease (Genzyme-legacy Pompe, Fabry, MS), and a growing oncology pipeline. Sanofi has been reshaping its R&D portfolio toward immunology and rare disease while spinning off its consumer health unit.

Scribe Therapeutics is a clinical-stage gene editing company developing next-generation CRISPR-based therapies for serious genetic diseases.

Bioelectronic medicine company whose rechargeable vagus nerve implant delivers electrical doses to treat inflammatory and autoimmune disease, led by rheumatoid arthritis.

Swedish Orphan Biovitrum (Sobi) is a global specialty biopharmaceutical company focused on rare diseases, with a portfolio spanning hematology, immunology, and specialty care. The company markets hemophilia treatments (Eloctate, Alprolix), immunology products (Kineret, Gamifant), and specialty therapeutics, and is expanding its rare-disease pipeline through both internal R&D and acquisitions.

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, produces, and markets affordable generic and specialty medicines, with a leading position in generic drugs and a growing specialty portfolio focused on central nervous system disorders, immunology, and respiratory conditions.

Clinical-stage immunoregulatory therapeutics company built on tissue regulatory T cell biology, combining high-resolution human tissue sequencing, computational biology and translational assay systems in its Deep Biology platform.

Vera Therapeutics is a late-stage clinical biopharmaceutical company developing treatments for serious immunological diseases. Its lead asset atacicept (a dual BAFF/APRIL inhibitor) received FDA approval in 2026 for IgA nephropathy (IgAN), establishing it as the first-in-class targeted therapy for this kidney disease.

AI-driven drug discovery company applying generative models and machine learning to small molecule and biologics design.